Видео с ютуба Cemiplimab

Cemiplimab Post-Treatment Considerations

Dr. Olszanski on Patient Selection for Cemiplimab Treatment in CSCC

Dr. Pavlick on the Safety Profile of Cemiplimab in CSCC

Реальные методы ведения пациентов, получающих цемиплимаб.

Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in p...

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

Neoadjuvant cemiplimab in patients with stage II-IV cutaneous squamous cell carcinoma

Cemiplimab in Managing Advanced cSCC

Patient Follow-Up After Receiving Cemiplimab

EPIC-A: cemiplimab with chemotherapy in penile carcinoma

Dr. Atlas on the Promise of Up-Front Cemiplimab in Locally Advanced CSCC

Dr. Rischin Discusses Cemiplimab in Cutaneous Squamous Cell Carcinoma

Cemiplimab reduces disease recurrence as adjuvant therapy for cutaneous squamous cell carcinoma

Investigating the role of cemiplimab in non-small cell lung cancer

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma

Benefit With Cemiplimab in Patients With mCSCC

EMPOWER-Lung 3: Cemiplimab Plus Chemotherapy in Advanced NSCLC With Dr. Ana Baramidze

FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma

C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma

Dr. Pavlick on Longer Follow-Up Data With Cemiplimab in CSCC